RxSight, Inc. (NASDAQ:RXST) Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC decreased its position in RxSight, Inc. (NASDAQ:RXST) by 80.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,441 shares of the company’s stock after selling 9,920 shares during the quarter. Acadian Asset Management LLC’s holdings in RxSight were worth $146,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. RA Capital Management L.P. boosted its holdings in RxSight by 1.1% in the first quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock worth $177,581,000 after purchasing an additional 38,540 shares during the period. Vanguard Group Inc. lifted its position in shares of RxSight by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock worth $78,634,000 after buying an additional 40,500 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in shares of RxSight by 34.5% in the 4th quarter. Parkman Healthcare Partners LLC now owns 513,032 shares of the company’s stock valued at $20,685,000 after buying an additional 131,701 shares during the period. Baillie Gifford & Co. grew its position in shares of RxSight by 438.8% during the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after buying an additional 291,733 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in RxSight by 21.7% during the second quarter. Victory Capital Management Inc. now owns 214,703 shares of the company’s stock worth $12,919,000 after acquiring an additional 38,349 shares during the period. 78.78% of the stock is currently owned by institutional investors.

RxSight Stock Performance

NASDAQ:RXST opened at $52.98 on Friday. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -42.02 and a beta of 1.22. RxSight, Inc. has a 1 year low of $20.66 and a 1 year high of $66.54. The business has a fifty day moving average of $50.87 and a 200-day moving average of $53.97.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $34.89 million during the quarter, compared to the consensus estimate of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The firm’s revenue for the quarter was up 67.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) earnings per share. On average, equities research analysts predict that RxSight, Inc. will post -0.81 EPS for the current year.

Insider Activity

In related news, insider Ilya Goldshleger sold 9,000 shares of RxSight stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.25, for a total transaction of $353,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,658,155.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other RxSight news, insider Ilya Goldshleger sold 9,000 shares of RxSight stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.25, for a total value of $353,250.00. Following the transaction, the insider now owns 42,246 shares in the company, valued at $1,658,155.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now directly owns 13,938 shares in the company, valued at approximately $816,906.18. The disclosure for this sale can be found here. Insiders own 9.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Oppenheimer dropped their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. BTIG Research raised their target price on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Stifel Nicolaus lowered their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight presently has an average rating of “Buy” and an average price target of $60.14.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.